ArticleBiomedical reports2025
Proteomic analysis identifies novel molecular signatures and immune-metabolic pathways in rheumatoid arthritis-associated interstitial lung disease.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood protein biomarkers for rheumatoid arthritis patients complicated by interstitial lung disease.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA)-associated interstitial lung disease (RA-ILD) is a severe extra-articular manifestation of RA characterized by complex pathogenesis and limited therapeutic options. The present study aimed to identify circulating serum proteins that may reveal novel molecular mechanisms underlying RA-ILD and inform the development of disease-modifying strategies. A multi-center cohort study was conducted including patients with RA-ILD (n=40), patients with RA but without ILD (n=40) and healthy controls (n=7). Pooled serum samples were analyzed using a high-throughput antibody array targeting 440 proteins. Differentially expressed proteins were defined by statistical criteria (P<0.05) and a fold change >1.2 or <0.83. Functional enrichment and protein-protein interaction (PPI) analyses were performed to explore associated biological pathways. A total of 20 proteins that showed a stepwise increase in expression were identified: Levels were significantly higher in patients with RA compared with healthy controls and further elevated in patients with RA-ILD relative to RA alone. Hierarchical clustering and principal component analysis revealed distinct protein expression profiles across groups. Gene Ontology analysis indicated enrichment in pathways related to immune cell activation, proliferation and cytokine production. Kyoto Encyclopedia of Genes and Genomes pathway analysis highlighted cytokine-cytokine receptor interactions and PI3K-Akt signaling. PPI network analysis identified insulin as a central hub interacting with IGF-1R, IL-7, and other profibrotic mediators. Several proteins (for example, CA9, EDA-A2, Gas1, CRTAM, IL-2Rb and IL-31) emerged as novel candidates not previously linked to RA-ILD. The present study identified a panel of 20 dysregulated serum proteins in RA-ILD, implicating immune dysregulation, fibrotic processes and metabolic signaling-particularly the insulin/IGF-1R-PI3K-Akt axis-in disease pathogenesis. These findings provide potential therapeutic targets for RA-ILD that warrant further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.